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DOI 10.1016/j.ccr.2012.03.042SUMMARYRescuing the function of mutant p53 protein is an attractive cancer therapeutic strategy. Using the National
Cancer Institute’s anticancer drug screen data, we identified two compounds from the thiosemicarbazone
family that manifest increased growth inhibitory activity in mutant p53 cells, particularly for the p53R175
mutant. Mechanistic studies reveal that NSC319726 restores WT structure and function to the p53R175
mutant. This compound kills p53R172H knockin mice with extensive apoptosis and inhibits xenograft tumor
growth in a 175-allele-specific mutant p53-dependent manner. This activity depends upon the zinc ion
chelating properties of the compound as well as redox changes. These data identify NSC319726 as
a p53R175 mutant reactivator and as a lead compound for p53-targeted drug development.INTRODUCTION
TP53 is the most frequently mutated gene in human cancer with
mutation frequencies ranging from 38%–50% in some reports to
as high as 75% and 96% in pancreatic adenocarcinoma and
high-grade serous ovarian carcinomas, respectively (Hingorani
et al., 2005; Cancer Genome Atlas Research Network, 2011;
Petitjean et al., 2007). The majority of mutations are mis-sense
mutations that occur most frequently in six ‘‘hotspot’’ codons
within the DNA binding domain (Olivier et al., 2010). These
mutant proteins are classified as either DNA contact mutants
(e.g., p53R273H) when the mutation occurs in a DNA binding
residue or conformational mutants (e.g., p53R175H) when
a conformational change causes a loss of WT p53 DNA binding.
Mutant p53 proteins are found at high concentrations in tumor
cells relative toWT p53,mostly because of a loss ofWT p53 tran-
scription of theMDM2 gene that negatively regulates p53, aswell
as other tumor-specific alterations, such as loss of p16INK4a
(Haupt et al., 1997; Midgley and Lane, 1997; Terzian et al.,
2008). The concept that these mutant proteins are functionalSignificance
The next generation of anticancer drugs will be defined by com
cells undisturbed. We developed an in silico screening method
cancer cells with a p53R175 mutation. The mechanism of actio
using its zinc-chelating and redox properties. This unique m
compounds that renature other p53mutants that fail to coordin
cancer, and the p53R175 mutant is the third most frequently fo
United States for this drug would approximate 32,000 annually
614 Cancer Cell 21, 614–625, May 15, 2012 ª2012 Elsevier Inc.and regulate important processes relevant to tumor biology is
referred to as the mutant p53 gain-of-function (GOF) phenotype
(Sigal and Rotter, 2000). Properties attributed to mutant p53
GOF include enhanced tumorigenesis, invasion, and metastasis
(Adorno et al., 2009; Dittmer et al., 1993; Liu et al., 2000; Muller
et al., 2009). Taken together, these properties make mutant p53
an attractive target for drug development.
The National Cancer Institute’s (NCI) anticancer drug screen
has reported growth inhibition half maximal inhibitory concentra-
tion (IC50) on 48,129 compounds tested on a panel of sixty
human tumor cell lines (NCI60 screen). Given that the p53 status
(WT, null, or mutant) of these cell lines is known (Ikediobi et al.,
2006; Shoemaker, 2006), we hypothesized that this screen could
be used to uncover drugs targeting p53mutant tumors. Thus, we
developed amethodology to identify compounds with increased
activity in a panel of tumor cell lines with p53 mutations, relative
to p53 WT controls. In this study, we attempted to validate this
methodology using two compounds that belong to the thiosemi-
carbzone family of metal ion chelators. We further investigated
one of the compounds with particular toxicity to cell linespounds that selectively kill cancer cells while leaving normal
ology that identified such a compound that selectively kills
n restores WT structure and function to the p53R175 protein
echanism may allow medicinal chemistry to design other
ate zinc. TP53 is themost commonlymutated gene in human
und mis-sense mutant. The potential pool of patients in the
.
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anism of this toxicity and the properties of the compound that are
relevant to this mechanism.
RESULTS
Identification of Thiosemicarbazones with Activity
in Cell Lines Expressing Mutant p53
Our methodology deals with the intrinsic heterogeneities of the
NCI60 screen (Figure 1A; Supplemental Experimental Proce-
dures available online). This takes as input IC50 data, applies
data normalization to obtain a working definition of a good
response, and then ranks compounds manifesting a good
response using a scoring function. This score function identifies
those compounds with an enrichment of good responders in
the case group (mutant p53), while simultaneously having
a depletion of good responders in the control group (wild-type
p53). To reduce the heterogeneity in the mutant p53 group,
we focused on mutations in hotspot codons 175, 248, and
273 (11 cell lines), whereas the control group was composed
of sixteen p53 wild-type cell lines. Applying this methodology,
we observed that three of the highest scoring compounds
belonged to the thiosemicarbazone family (NSC319725,
NSC319726, and NSC328784), which preferentially inhibited
p53 mutant cell lines (Figure 1B). When comparing the IC50s of
these compounds by p53 mutational status, we see that the
low IC50s are enriched of cells with a p53 mutation (Figure 1B,
red), whereas the majority of p53 wild-type cells exhibit high
IC50s (Figure 1B, blue). In contrast, two reported mutant p53
reactivators (PRIMA-1 and MIRA-1), as well as an additional thi-
osemicarbazone currently in clinical trials (Triapine), scored
poorly using this methodology in comparison to NSC319726
(Figures S1A–S1D).
We validated two of our screened compounds (NSC319725
and NSC319726) using a mouse fibroblast cell line containing
no functional TP53 gene (10(3)), fromwhich several stable human
cytomegalovirus-driven mutant p53 transfectants (175, 248, and
273) were derived (Dittmer et al., 1993). Balb/c 3T3 fibroblasts
were used as a p53 WT control because this is the same back-
ground as the 10(3) and its derived cell lines. Both compounds
exhibited growth inhibition at markedly lower concentrations in
cells expressing mutant p53 as compared to the WT control,
particularly in the 175 allele (Figure 1C). The IC50 for the
NSC319725 treated 175 mutant was R100-fold lower than the
WT. For NSC319726, the effect was even greater as the IC50
for the 175 mutant was 8 nM, whereas the IC50 of the WT was
not reached. Similar to the Balb/c 3T3, these two compounds
were remarkably nontoxic to WI38 human fibroblasts (p53 WT),
as an IC50 for both compounds was not obtained (Figure 1D).
Furthermore, NSC319726 did not induce WT p53 protein levels
or transcriptional activity as common cytotoxic agents, such as
etoposide, do in vitro (Figure S1E).
We further validated NSC319726 by employing additional
p53 mutant cell line systems. In a set of isogenic mouse embry-
onic fibroblast (MEF) cell lines from p53+/+, p53/, and
p53R172H/R172H mice, we found that NSC319726 exhibited a
much higher sensitivity for the MEF-p53R172H/R172H cell line as
compared to the p53+/+ and p53/ controls (Figure 1E). We
compared the sensitivities across human tumor cell lines withdifferent p53 ‘‘hot spot’’ mutations (175, 248, and 273). With
the exception of one p53R175 cell line (RXF393), the 175 cells
exhibited similar IC50’s that were approximately 10-fold and in
some instances 100-fold lower than the other hotspot mutants,
indicating a 175 allele preference of growth inhibition by
NSC319726 (Figure 1F). It is important to emphasize that the
results of these assays depend to a significant degree on a
number of factors, including themethod of assaying cell viability,
the proliferation rates of the cells, and the confluency at the
time of drug exposure, as well as differences in redox in tumor
cells. To diminish intra-assay variability, we used the Guava-
ViaCount assay to compare the effects of NSC319726 across
tumor cell lines that varied by p53 status given the heterogeneity
of these cell lines. In both the MTS and Guava-ViaCount assay,
we found it to be important to have the cells at 50%–60% con-
fluency at the time of drug exposure. Cell growth inhibition
assays carried out under different conditions can and do give
different IC50s.
Induction of p53R175-Dependent Apoptosis
by NSC319726
To determine if the inhibition of cell growth was mediated by
apoptosis, we performed Annexin-V staining of different cell
lines treated with NSC319726. We observed an increase in the
number of Annexin-V-stained cells with a maximum increase in
the 175 mutant (Figure 2A). Similarly, treatment of three different
ovarian carcinoma cell lines (TOV112D [p53R175H], OVCAR3
[p53R248W], and SKOV3 [p53/]) with NSC319726 resulted in
an induction of apoptosis in the p53R175 mutant more than
2-fold higher than the other two mutant cell lines (Figure 2B).
When we silenced expression of the p53R175 mutant protein by
siRNA, we observed a marked reduction in sensitivity to cell
growth inhibition, demonstrating that the NSC319726 mecha-
nism is at least partially dependent on the p53R175mutant protein
(Figure 2C).
NSC319726 Induction of a ‘‘WT-like’’ Conformational
Change in the p53R175 Mutant Protein
Because NSC319726 induced a p53 apoptotic function in
p53R175 cells, we investigated if NSC319726 restored WT
conformation to the mutant p53R175 protein. Using conforma-
tion-specific antibodies by immunoflourescence, we observed
that NSC319726 induced a conformation change in the
p53R175 mutant to a structure that was recognized by the WT-
specific antibody (PAB1620) and was no longer recognized by
the mutant-specific antibody (PAB240; Figure 3A). Quantifica-
tion of the fluorescence intensity for PAB240 was reduced by
5-fold, whereas that of PAB1620 was increased by 2-fold (Fig-
ure 3B). We confirmed this conformation change by PAB240
immunoprecipitation of NSC319726-treated TOV112D lysates,
indicating a more than 85% decrease in PAB240 immunoreac-
tivity (Figure 3C). Next, we sought to confirm this conformation
change in an additional cell line. NSC319726 treatment of
a MEF cell line derived from p53R172H/R172H mice resulted in
a loss of PAB240 immunofluorescence staining (Figure 3D).
The PAB1620 antibody staining is not shown because this anti-
body is human-specific. This demonstrates that the conforma-
tion change induced by NSC319726 occurs in both human
(p53R175) and mouse (p53R172) proteins.Cancer Cell 21, 614–625, May 15, 2012 ª2012 Elsevier Inc. 615
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Figure 1. Identification of Thiosemicarbazones with Activity in Cell Lines Expressing Mutant p53
(A) Flow diagram of the in silico screen methodology.
(B) IC50 distribution and chemical structure of the thiosemicarbazones aligning lower IC50s to higher IC50s in cells with mutant p53 (red) and WT p53 (blue),
analyzed with the NCI60 data set. In the NCI60 data set, the human tumor cell lines are treated with five serial dilutions of each compound for 48 hr at 37C.
(C) Validation of the sensitivity of the compounds in the cell lines expressing mutant p53. Cell growth inhibition assays using a mouse embryonic fibroblast (MEF)
cell line system consisting of (10)3 (p53/), (10)3/175, (10)3/248, (10)3/273, and 3T3 (p53+/+). (Left panel) Growth inhibition with NSC319726. (Right panel) Growth
inhibition with NSC319725.
(D) Sensitivity to NSC319726 in a set of isogenic MEF cell lines from p53+/+, p53/, and p53R172H/R172H mice.
(E) NSC319725 and NSC319726 do not inhibit cell growth of WI38 (p53+/+) human fibroblasts.
(F) The sensitivity of NSC319726 in human tumor cell lines with hotspot p53 mutations. Cell growth inhibition was analyzed by MTS assay (C) or by Guava
ViaCount assay (D–F). In both the MTS and Guava ViaCount assays, cells were treated with five to seven serial dilutions of the compounds (0.00001 to 10 mM) for
3 days. The error bars are ± SD.
See also Figure S1.
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Figure 2. The p53-175-Mutant-Dependent Apoptosis Induced by NSC319276
The apoptosis is measured with Annexin-V staining using Guava Nexin reagent and Guava PCA instrument.
(A) Apoptosis is measured in the (10)3-derived MEF cells.
(B) Apoptosis is measured in a panel of ovarian cancer cell lines, TOV112D (p53R175H), OVCAR3 (p53R248W), and SKOV3 (p53/). The treatment is 1 mM
NSC319726 (as in the other figures, unless described differently) for 24 hr.
(C) Growth inhibition by NSC319726 in TOV112D cells with siRNA knockdown of p53R175H mutant protein, measured as in Figure 1E.
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the ‘‘WT-like’’ Conformational Change Induced
by NSC319726
To determine if the conformation change observed with the
p53R175 mutant resulted in restoration of p53 transcriptional
function, we examined p21 protein levels after NSC319726
treatment in TOV112D and SKOV3 cells. We found that
NSC319726 induced p21 in the TOV112D cell line but not in
the SKOV3 (Figure 4A). Treatment of the TOV112D cells with
the DNA damaging agent etoposide failed to induce p21 (Fig-
ure 4A). This suggests that the p21 induction in NSC319726-
treated TOV112D cells was p53R175-mutant-dependent.
We note NSC319726 caused a reduction in the levels of the
mutant protein (Figure 4A). We examined this further by
measuring the mutant protein levels at different time points
over a 24 hr period. Treatment of TOV112D cells with
NSC319726 decreased the stabilization of the mutant protein
with the lowest levels seen at 6 hr with a return to pretreatment
levels by 24 hr. This p53 mutant protein destabilization was not
seen when we treated two cell lines containing the p53 DNA
contact mutants R248 (OVCAR3) and R273 (SW620) with
NSC319726. This indicates allele specificity to the NSC319726-
mediated effect on p53 mutant protein levels. We hypothesized
that the decrease in p53R175 protein stability was due to restora-tion of Mdm2 negative regulation of the ‘‘WT-like’’ p53R175
mutant. To test this, we performed this experiment in the pres-
ence of Nutlin-3 (small-molecule antagonist of Mdm2) and found
that Nutlin-3 abrogated the decrease in stability of the p53-175
mutant induced by NSC319726 (Figure 4B). This restoration
of Mdm2-negative regulation is the result of transactivation of
the MDM2 promoter by the ‘‘WT’’-like p53R175 mutant (Figures
4C and 4D).
We confirmed the ability of NSC319726 to restore DNA
binding properties to the p53R175 mutant protein by chromatin
immunoprecipitation (ChIP). Using the p53 antibody, DO-1,
ChIP analysis of NSC319726-treated TOV112D cells revealed
the restoration of site-specific DNA binding of p53R175 mutant
to the promoters of p21, PUMA, and MDM2 (Figure 4C).
HCT116 cells treated with etoposide, as well as RNA polymerase
II binding of the GAPDH promoter, were used as controls (Fig-
ure 4C). We compared the mRNA levels of several p53 targets
(p21, PUMA, and MDM2) in the TOV112D (p53R175H), OVCAR3
(p53R248W), and SKOV3 (p53/) cells upon treatment and found
that NSC319726 increased the levels of all three p53 target
genes in TOV112D cells, particularly the apoptotic gene PUMA
(Figure 4D). To provide further evidence that NSC319726
restored site-specific p53 transactivational function, we trans-
fected the TOV112D cells with a luciferase reporter plasmidCancer Cell 21, 614–625, May 15, 2012 ª2012 Elsevier Inc. 617
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Figure 3. A ‘‘WT-like’’ Conformational Change in
the p53-175 Mutant Protein Induced by NSC319726
(A) Immunoflourescence of TOV112D (p53R175H) cells
using p53-conformation-specific antibodies (PAB1620
for WT conformation and PAB240 for mutant conforma-
tion). The H460 cell line is used as a control to show that
the WT p53 conformation is not changed by NSC319726.
All scale bars represent a size of 25 mm.
(B) Quantification of PAB240 and PAB1620 staining
indicates significant differences upon treatment with
NSC319726 (p < 0.0001, t test). The error bars are ± SD.
(C) Immunoprecipitation of mutant p53 protein in
TOV112D cells using PAB240 and detected by p53
(FL393) by western blot.
(D) Immunoflourescence of MEF p53R172H/H cells using the
PAB240-mutant-specific antibody.
In all experiments (A, C, and D), cells are treated with
NSC319726 (1 mM) for 6 hr before harvesting for im-
munostaining or immunoprecipitation.
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promoter. NSC319726 treatment induced a 2.5-fold increase in
luciferase activity that was not seen in MEF cells expressing
the 248 and 273 alleles, indicating that the restoration of tran-
scriptional function is allele-specific (Figure 4E). We next utilized
gene expression microarrays to examine the transcriptional
activity of a larger cohort of p53 targets in TOV112D cells.
NSC319726 treatment produced a p53 target expression signa-
ture remarkably different from the untreated controls, confirming
that the conformation change of the p53R175 mutant results in
a transcriptionally active protein (Figure 4F). Table S1 reports
the average expression log2-ratios between cells treated with
NSC319726 and untreated controls, focusing on probes that
map to p53 target genes. The list of p53 targets were selected
from a literature review, providing a comprehensive list of exper-
imentally verified targets of p53 (Riley et al., 2008).
In Vivo Allele-Specific p53R175H Mutant Reactivation
by NSC319726
To investigate the p53 mutant’s reactivation in vivo, we per-
formed toxicity assays in p53+/+, p53/, and p53R172H knockin
mice (Lang et al., 2004). Mice were housed and treated accord-
ing to guidelines and all the mouse experiments are done with
the approval of the Institutional Animal Care and Use Committee
(IACUC) of UMDNJ-Robert Wood Johnson Medical School. We
hypothesized that p53R172H mice would experience greater
toxicity for a given dose of NSC319726 as compared to p53+/+
mice. By day 3 of treatment (10 mg/kg/day), all seven of the
p53R172H/R172H mice had died, whereas only one of nine p53+/+
mice had died. By day 4, the survival of the p53+/+ mice was
70%, whereas the survival of p53+/R172H was 30%, suggesting
a clear dosage effect that is dependent on the TP53R175 geno-
type (Figure 5A). Next, we lowered the dose to 5 mg/kg and
found that by day 7, the p53+/+ and p53/ mice exhibited
a 100% survival compared to only 30% of the p53R172H/R172H
mice (Figure 5A).618 Cancer Cell 21, 614–625, May 15, 2012 ª2012 Elsevier Inc.We examined the tissues of p53+/+ and p53R172H/R172H mice
after treatment for evidence of apoptosis as well as gene expres-
sion of a panel of p53 targets. We detected abundantly more
apoptotic cells in the sections of the spleen and thymus of
p53R172H/R172H mice as compared with the p53+/+ controls (Fig-
ure 5B). We also detected elevated mRNA levels of a number of
p53 targets in a tissue specific fashion in the p53R172H/R172Hmice
as compared with the p53+/+ controls, most notably in the lung,
spleen, thymus, and small intestine (Figure 5C).
We tested the ability of NSC319726 to inhibit the growth of
xenograft mouse tumors derived from human tumor cell lines
carrying different p53 alleles. At a dose of 1 mg/kg, tumor growth
of the H460 (p53+/+) and MDAMB468 (p53R273W) xenografts was
not inhibited relative to the vehicle control, whereas tumor
growth was significantly inhibited in the TOV112D (p53R175H)
xenografts (Figure 5D). When we lowered the dose 10-fold to
0.1 mg/kg in the TOV112Dmice, we observed only a small differ-
ence in tumor growth inhibition, demonstrating both a dosage
effect of the drug and a larger therapeutic window. Taken
together, these findings provide in vivo evidence for allele-
specific p53 mutant reactivation.
Zinc Ion Chelation and Redox Changes Are Important
for the NSC319726-Mediated p53R175 Reactivation
Mechanism
Thiosemicarbazones are metal ion chelators with a strong
affinity for iron, copper, and zinc (Yu et al., 2009). They have
been investigated as anticancer agents and have been shown
to inhibit DNA synthesis by inhibiting the iron-dependent
enzyme ribonucleotide reductase (RR) but at much higher
concentrations than are employed to inhibit the growth of
p53R175 mutant cells. To determine if the metal ion chelating
property of NSC319726 is important to its p53R175 mutant
activity we added NSC319726 to TOV112D cells in the presence
of various concentrations of FeSO4. We found that FeSO4 at
concentrations above 15 mM completely abrogated the activity
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of NSC319726 was inhibited in a dose-dependent manner
(Figure 6A).
We suspected iron was not the relevant metal ion, because
iron is not associated with the p53 protein, and the treatment
of the TOV112D cells with another iron chelator, desferrioxamine
(DFO), had no apoptotic effect (Figure S2A). However, zinc is
required for proper folding of WT p53, and the 175 mutant is
classified as a non-zinc-binding mutant because it fails to coor-
dinate zinc (Butler and Loh, 2003; Joerger and Fersht, 2007).
When we added NSC319726 to TOV112D cells in the presence
of different concentrations of ZnCl2, we found that there was
an optimal zinc concentration range (5–15 mM) in which the
activity of NSC319726 increased 2-fold (Figure 6B). We did not
test higher concentrations over 100 mM of ZnCl2 in combination
with NSC319726 because we found that concentrations above
100 mM of ZnCl2 (by itself) were toxic to cells. This toxicity was
independent of p53 status (Figures S2B and S2C).
Another property of thiosemicarbazones is their effect on the
redox state of the cell. Thiosemicarbazone:Fe complexes cause
oxidative stress by the creation of hydroxyl radicals through
Fenton chemistry (Kalinowski and Richardson, 2007; Richardson
et al., 2006, 2009). This is relevant to the mechanism of
NSC319726 as redox changes have been reported to influence
WT p53 folding (Hainaut and Milner, 1993a). In support of this,
we observed a statistically significant decrease in the levels of
the cellular reductant glutathione upon NSC319726 treatment
of TOV112D cells at 1, 3, and 24 hr (Figure 6C). To determine
the importance of these redox changes to the activity of
NSC319726 we treated TOV112D cells in the presence of the
reducing agent N-acteyl-cysteine (NAC) and the oxidizing agent
diamide. We found that 5 mM NAC inhibited the apoptotic
activity of NSC319726, whereas diamide (100 mM) enhanced it
(Figure 6D). These data suggest that ROS changes are important
for the apoptotic mechanism of NSC319726 on p53R175 mutant
cells.
DISCUSSION
The reactivation of p53 in mouse tumor models has been shown
to be a highly effective therapeutic strategy (Martins et al., 2006;
Ventura et al., 2007; Xue et al., 2007). Several small molecules
have been claimed to reactivate mutant p53, including CP-
31398, WR-1065, PRIMA-1, and MIRA-1 (Bykov et al., 2002,
2005; Foster et al., 1999; North et al., 2002). With the exception
of one compound, WR1065, all have been identified using tradi-
tional chemical screens (Bykov et al., 2002, 2005). Traditional
chemical screens favor the use of matched case/control cell
lines derived from the same parental cell line, engineered such
that the case cell line carries the molecular alteration under
consideration. This can be a fundamental caveat, because
cancers are known to be heterogeneous in nature. Here, we
demonstrate our methodology to screen for compounds mani-
festing increased sensitivity in a panel of cell lines carrying p53
mutations independently of their diverse genetic backgrounds
and cell type specificity, which is a more realistic model of
what is observed in the clinic. Applying this methodology to
the NCI60 screen we identified three compounds from the thio-
semicarbazone family. Follow up experiments with two of thesecompounds (NSC319725 and NSC319726) corroborated the
predicted p53-mutant-specific growth inhibitory properties. It
is possible that this methodology could be used to identify
compounds with increased sensitivity in tumor cell lines carrying
mutations in other major oncogene/tumor suppressor pathways.
It is important to note that cell viability assays in Figure 1C and
the apoptosis assays in Figure 2A indicate that there is an
apoptotic mechanism that is independent of p53 mutational
status (null, mis-sense mutant). What initiates this apoptosis is
unclear but may be related to either an increase in ROS levels
or ribonucleotide reductase (RR) inhibition, two reported mech-
anisms of action for thiosemicarbazones. Nontumor cell lines
with a WT p53 gene (Balb/c 3T3, WI38) showed relatively little
to no growth inhibition by NSC319726 at these same doses,
which would argue against the inhibition of RR as the explana-
tion. If increased ROS levels are the reason, we speculate that
this apoptosis may be due to the inability to compensate for
these oxidative changes in a cell lacking a functional p53 tran-
scription factor.
In distinction, the mechanism of apoptosis in a p53R175 mutant
cell is dependent on the mutant p53R175 mutant protein.
NSC319726 treatment induces aWT-like conformational change
in the p53R175 mutant protein that restores sequence-specific
p53 transcription. This is best observed in the in vivo experi-
ments employing both knockin p53mutant mice and xenografts.
We have demonstrated that the metal ion chelating properties
of NSC319726 are required for the mutant-p53-mediated
apoptotic activity. Interestingly, metal ion chelation has been
shown to induce p53 conformational changes (Hainaut and
Milner, 1993b; Yu et al., 2009). The fact that the 175 mutant
fails to bind zinc and that zinc chloride at low concentrations
(5–15 mM) enhances the activity leads us to hypothesize that
NSC319726 may serve as a source of zinc to allow the 175
mutant to refold. Such ametallochaperone function was demon-
strated for another zinc chelator, Nitriloacetate, which facilitated
refolding of the p53WTDNAbinding domain (that was previously
unfolded by removing the zinc; Butler and Loh, 2007). Further
biophysical studies are needed to confirm this.
Structural studies of the p53 DNA binding domain indicate that
the zinc ion is coordinated by four amino acids (C176, H179,
C238, and C242; Cho et al., 1994; Joerger et al., 2005; Wong
et al., 1999). Mutations in any of these residues result in the
inability to coordinate zinc. In contrast, the R175H mutant is
not directly involved in zinc binding. It is generally believed that
a histidine residue at this location induces structural distortions
in the protein that prevent it from binding zinc (Joerger and
Fersht, 2007). If the metallochaperone hypothesis is correct
then it is plausible that NSC319726 may reactivate other zinc
binding mutants.
The question of what activates mutant p53 to become a better
transcription factor and induce an apoptotic mechanism after
a WT conformational change is an important one. Most likely
this is due to the elevated oxidative state in the mutant p53
cell. This oxidative state is the result of the combination of
NSC319726 treatment and elevated ROS levels in p53 mutant
cells (due to loss of p53-mediated regulation of the redox state;
Sablina et al., 2005). In support of this is the observation that an
oxidizing agent, diamide, enhances the apoptotic activity of
NSC319726, whereas NAC inhibits it.Cancer Cell 21, 614–625, May 15, 2012 ª2012 Elsevier Inc. 619
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Cancer Cell
Allele-Specific Mutant p53 Reactivating CompoundWhereas inhibition of RR activity is a known mechanism of
action of thiosemicarbazones, we feel this is unlikely involved
in the p53R175 reactivation mechanism because (1) the drug is
completely nontoxic to human fibroblasts at the IC90 for
p53R175 mutant cells and (2) the dose that inhibited p53R175
mutant xenograft tumor growth was completely nontoxic to
mice. However, the doses we used in our mouse toxicity exper-
iments were considerably higher, and RR inhibition may explain
some of the toxicity observed in WT mice.
NSC319726 is an attractive lead compound for drug develop-
ment for three reasons:
(1) In vivo p53R175 mutant reactivation can be observed at
doses that are nontoxic to WT animals;
(2) The compound exhibits a wide therapeutic window when
given intravenously; and
(3) The target (p53 mutant protein) is found at high levels in
cells.
The pool of potential patients for such a drug would be fairly
large given the fact that the 175 mutant is the third most
commonly found p53 mis-sense mutant, making up an esti-
mated 5.5% of all mis-sense mutants (Olivier et al., 2010). Using
the IARC TP53 database (http://www-p53.iarc.fr/), we estimate
the annual incidence in the United States of cancer patients
carrying the TP53R175 allele to be more than 32,000. Our findings
support the growing trend in developmental therapeutics in
which the efficacy of future cancer drugs will depend upon the
knowledge of the patient’s tumor genotype.EXPERIMENTAL PROCEDURES
Cell Lines and Culture Conditions
The mouse embryonic fibroblasts (MEFs) (10)3 and its derived cell lines
with various human p53 mutations (R175, R248, and R273) were previously
derived (Dittmer et al., 1993). 3T3 is derived from Balb/c and has p53+/+
alleles. MEF p53R172H/R172H, MEF p53+/+ and MEF p53/ cells are derived
from C57BL/6 mice. All MEF cells are cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% FBS. TOV112D and WI38 are cultured
in DMEM with 10% FBS. SKOV3 is cultured in McCoy’s 5A with 5% FBS.
H460 and MCF7 are cultured in RPMI with 10% FBS. HCT116 is cultured
in McCoy’s 5A with 10% FBS. OVCAR3 is cultured in RPMI1640 with
20% FBS.
MTS Assay and Viability Assay
MTS assay is done in accordance with the manufacturer’s instructions
(Promega, Madison, WI, USA). In brief, 5,000 cells of TOV112D cells (5,000
cells/well, in 100 ml culture) are cultured in 96-well plate to reach the 50%–
60% confluence on the second day when treated with serial dilutions of the(C) Chromatin immunoprecipitation (ChIP) assay. Lysates from TOV112D cells tre
for 6 hr are subject to immunoprecipitation using anti-p53 antibody (DO-1) follow
HCT116 treated with etoposide is used as a positive control for functional p53 D
GAPDH is also used as a positive control.
(D) qRT-PCR of p21,MDM2, and PUMA in TOV112D, OVCAR3, and SKOV3 cells
cells using a Qiagen RNeasy kit, and the gene expression level is measured by q
(E) TOV112D cells are transfected with a plasmid bearing the 20 bp p53 respons
(1 mM) for 24 hr, followed by luciferase reporter assay. The error bars are ± SD.
(F) Microarray analysis of NSC319726 (1 mM, 24 hr) treated and control TOV112D
presented in Table S1. The heatmap is shown with the color scale indicating fo
database with accession number GSE35972.
See also Table S1.compounds. The growth is measured by MTS reagent and Victor Plate reader
instrument (PerkinElmer, Waltham, MA, USA) after incubation for 3 days.
Viability assays are done in accordance with the manufacturer’s instructions
for Guava ViaCount (Millipore, Billerica, MA, USA). In brief, the cells (5 3
104 cells/well, in 1 ml culture) are cultured in a 12-well plate to reach the
50%–60% confluence on the second day when treated with serial dilutions
of the compound. The growth is measured by Guava ViaCount reagent and
Guava PCA instrument after incubation for 3 days.
Apoptosis Assay Using Annexin Staining
The Annexin staining is done in accordance with the manufacturer’s instruc-
tions (Millipore). In brief, the cells are cultured in 12-well plate, followed by
treatment with the compound for different time periods. The cells are stained
with the Nexin staining reagent and Annexin-positive cells are detected with
the Guava PCA instrument.
Transfection of p53 siRNA
The siRNA transfection is done with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA), following the manufacturer’s instructions. The p53 siRNA is from
SMARTpool (Thermo Scientific/Dharmacon, Lafayette, CO, USA).
Immunofluorescent Staining
The cells are grown on the coverslip, followed by various treatments. The
coverslips are fixed with 4% paraformaldehyde for 10 min and then permeal-
ized with 0.5% Triton X-100 for 5 min. The conformation of the mutant and WT
p53 proteins can be recognized specifically by the antibodies PAB1620 (1:50,
recognizingWT conformation) and PAB240 (1:200, recognizingmutant confor-
mation) stained overnight, respectively. The secondary antibody, goat anti-
mouse IgG is incubated for 40 min. PAB1620 and PAB240 are from EMD
Chemicals (Gibbstown, NJ, USA). Fluorescent staining intensity was quanti-
fied using Adobe Photoshop.
Immunoprecipitation
The cell lysates (500 mg) with various treatments are subjected to immunopre-
cipitation with ExctaCruz matrix (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) using the antibody PAB240 (4 mg). The pull-down is detected by western
blot with p53 (FL393; Santa Cruz Biotechnology), which recognizes all formats
of the p53 protein. The density of the image relative to the control is determined
using Adobe Photoshop.
Immunohistochemistry Staining
The mouse tissues are harvested and are subjected to immunohistochemistry
(IHC) staining with cleaved caspase-3 (CC3, 1:100; Cell Signaling, Danvers,
MA, USA).
Western Blot
The lysates (or immunoprecipitated products) are run on SDS-PAGE and
transferred onto polyvinylidene fluoride membranes. The detection of the
protein level is done with the manufacturer’s instructions (ECL, GE Healthcare,
Waukesha, WI, USA). The p21 antibody is from EMD Chemicals. The GADPH,
p53 (DO-1) and actin antibodies are from Santa Cruz Biotechnology. The
density is determined using Adobe Photoshop and is expressed as the ratio
to the loading control (GAPDH) relative to the control.ated with NSC319726 (1 mM) and HCT116 cells treated with etoposide (20 mM)
ed by PCR of p53 recognition elements (p53REs) of p21, PUMA, and MDM2.
NA-binding property. ChIP with anti-RNA polymerase II antibody and PCR for
with treatment of NSC319726 (1 mM) for 24 hr. The RNA is extracted from the
uantitative RT-PCR using TaqMan gene expression assays.
e element (p53RE) in p21 promoter region and then treated with NSC319726
cells comparing gene expression levels of p53 targets. The list of the genes is
ld change. The data from the microarrays have been deposited in the GEO
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Figure 5. In Vivo Evidence of NSC319726-Mediated p53-175 Mutant Reactivation
(A) Toxicity assays of NSC319726 in p53R172H/R172H, p53+/+, and p53/ mice. Mice in the top panel are administered 10 mg/kg by daily intraperitoneal (i.p.)
injection for up to 7 days. Mice in the bottom panel are administered 5 mg/kg daily (i.p.) for up to 7 days.
(B) Immunohistochemical stainingwith cleaved caspase-3 antibody of spleen and thymic tissues in p53+/+ and p53R172H/R172Hmice. All scale bars represent a size
of 100 mm.
(C) qRT-PCR of mRNA levels of several p53-regulated genes in p53+/+ and p53R172H/R172H mouse tissues. The inductions of over 1.73 are highlighted
in bold.
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Figure 6. Zinc Ion Chelation and Redox Changes Are Important for the NSC319726-Mediated p53-175 Mutant Reactivation
(A) TOV112D cells are treated with NSC319726 with or without the presence of various concentrations of FeSO4, followed by measurement of growth inhibition.
The NSC319726 activity is shown as 1/IC50 for cell growth inhibition.
(B) TOV112D cells are treated with NSC319726 with or without addition of various concentrations of ZnCl2, followed by measurement of growth inhibition.
The NSC319726 activity is shown as 1/IC50 for cell growth inhibition.
(C) Ratio of reductant GSH and oxidative GSSG in the p53R175H cells upon NSC319726 (1 mM) treatment is measured at several time points (p = 0.0057 at 1 hr,
p = 0.0027 at 3 hr, and p = 0.001 at 24 hr, t test). The error bars are ± SD.
(D) TOV112D cells are treated with NSC319726 using six serial dilutions (0.001 to 2 mM) with either N-acetyl cysteine (NAC, 5 mM) or diamide (100 mM) for 3 days.
The growth inhibition was analyzed by MTS assay as in Figure 1C. The error bars are ± SD.
See also Figure S2.
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The p53 recognition element (p53RE) in the p21 promoter region, constructed
in pGL3 vector, is from Dr. Prives’ laboratory (Columbia University, New York,
NY, USA). It is transfected into the cells, followed by the treatment of
NSC319726. The cell lysate is made and the luciferase reporter assay is
done in accordance with the manufacturer’s instructions (Promega).
Chromatin Immunoprecipitation and PCR
ChIP experiments are done using an EpiTect Chip One-Day Kit in accordance
with the manufacturer’s instructions (Qiagen, Venlo, The Netherlands). The
recovered ChIP DNA is subject to PCR using primers flanking the p53
response elements (p53REs) in the p21, PUMA, and MDM2 genes. They are
p21-F: 50-GTGGCTCTGATTGGCTTTCTG, p21-R: 50-CTGAAAACAGGCAGC
CCAAGG; PUMA-F: 50-TCCTTGCCTTGGGCTAGGCC, PUMA-R: 50-CGCGG
ACAAGTCAGGACTTG; and MDM2-F: 50-GGTTGACTCAGCTTTTCCTCTTG,(D) Efficacy assays of NSC319726. Xenograft tumors are generated using H460, M
intravenous administration of NSC319726 at 1 or 0.1 mg/kg (TOV112D only). Tum
H460 (Control-5, Treatment-5), MDAMB468 (Control-9, Treatment-8), TOV112D
are ± SD.MDM2-R: 50-GGAAAATGCATGGTTTAAATAGCC. The control primers are
used for PCR of GAPDH provided by the kit.
RNA Extraction and Quantitative RT-PCR
RNA is extracted from the cells or mouse tissues using a Qiagen RNeasy Kit,
and the gene expression level is measured by quantitative RT-PCR using
TaqMan gene expression assays (Applied BioSciences, Carlsbad, CA, USA).
The gene expression level is normalized with b-actin, and the average is pre-
sented with standard deviation from duplicates or triplicates of repeated
experiments.
Microarray Assay
GeneChipHumanGenomeU133 Plus 2.0 array is fromAffymetrix (Santa Clara,
CA, USA). The RNA is extracted from the cells with or without treatment with
NSC319726 and subject to microarray assay. The list of p53 targets wereDAMB468, and TOV112D cells and are allowed to grow to 60mm3 prior to daily
or measurements are mean ± SD. The following number of animals were used,
(Control-7, Treatment 1mg/kg-7, 0.1 mg/kg-7). CTL is control. The error bars
Cancer Cell 21, 614–625, May 15, 2012 ª2012 Elsevier Inc. 623
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Allele-Specific Mutant p53 Reactivating Compoundselected from a literature review, providing a comprehensive list of experimen-
tally verified targets of p53 (Riley et al., 2008).
Measurement of Level of Glutathione
The levels of reduced glutathione (GSH) and oxidized glutathione (GSSG) are
measured using the GSH-Glo Glutathione Assay in accordance with themanu-
facturer’s instructions (Promega).
Mouse Experiments
Mice are housed and treated in accordance with guidelines and all the mouse
experiments are done with the approval of Institutional Animal Care and Use
Committee (IACUC) of the UMDNJ-Robert Wood Johnson Medical School.
Themicewith p53R172H/+ are a gift of Dr. Lozano (MDAnderson Cancer Center,
Houston, TX, USA). The nude mice NCR nu/nu were purchased from Taconic.
For the toxicity assays, 6- to 10-week-old mice were of the following geno-
types, p53R172H/R172H (n = 8), p53R172H/+ (n = 8), p53+/+ (n = 9), and p53/
(n = 3). Mice were treated with either NSC319726 at 10 or 5 mg/kg or vehicle
control (dimethyl sulfoxide) by intraperitoneal injection daily for up to 7 days,
followed by harvesting the mouse tissues. Xenografts tumor assays are
derived from the human tumor cell lines, TOV112D, H460, and MDAMB468
(6 3 106 cells/mouse). Tumor dimensions were measured every other day,
and their volumes were calculated by length (L) and width (W) by using the
formula: volume = L3W23p/6. Tumors were allowed to grow to 60mm3 prior
to daily intravenous administration of NSC319726 at 1 or 0.1 mg/kg (TOV112D
only). The following number of animals were used, H460 (Control-5, Treat-
ment-5), MDAMB468 (Control-9, Treatment-8), and TOV112D (Control-7,
Treatment 1mg/kg-7, 0.1mg/kg-7). The experiment was repeated two to three
times with similar results.
ACCESSION NUMBERS
The data from the microarrays have been deposited in the GEO database with
the accession number GSE35972.
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